Cargando…

The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia

Background: The response to BoNT is not uniform; a broad spectrum of responses and side-effects usually occurs. This study aimed to show special cervical dystonia cases with therapy response very different to normal treatment course which indicate the extreme ends of therapy spectrum. Patients: Clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Samadzadeh, Sara, Brauns, Raphaela, Hefter, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824374/
https://www.ncbi.nlm.nih.gov/pubmed/33396548
http://dx.doi.org/10.3390/toxins13010022
_version_ 1783640061684744192
author Samadzadeh, Sara
Brauns, Raphaela
Hefter, Harald
author_facet Samadzadeh, Sara
Brauns, Raphaela
Hefter, Harald
author_sort Samadzadeh, Sara
collection PubMed
description Background: The response to BoNT is not uniform; a broad spectrum of responses and side-effects usually occurs. This study aimed to show special cervical dystonia cases with therapy response very different to normal treatment course which indicate the extreme ends of therapy spectrum. Patients: Clinical data and course of treatment of five long-term treated patients with cervical dystonia out of therapy response norms are presented: a patient who was supersensitive to standard dose and has required dose adjustment to lower dose of BoNT; one patient who worsened under a standard dose, but responded excellently to twice the standard dose; one insensitive patient who responded poorly for years to a dose well above the standard dose, but responded when dose was further increased; and two patients with a totally different response pattern to BoNT/A preparation 1, but the development of a neutralizing antibody induced secondary treatment failure in both cases and a totally different response after switch to BoNT/A preparation 2. Conclusions: These five patients indicate that the response of a patient to a BoNT preparation may be unexpected. Therefore, cautious onset of BoNT therapy is recommended as well as consequent dose adjustment later on and even switch to another BoNT/A preparation when a patient has already developed NABs against BoNT/A.
format Online
Article
Text
id pubmed-7824374
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78243742021-01-24 The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia Samadzadeh, Sara Brauns, Raphaela Hefter, Harald Toxins (Basel) Communication Background: The response to BoNT is not uniform; a broad spectrum of responses and side-effects usually occurs. This study aimed to show special cervical dystonia cases with therapy response very different to normal treatment course which indicate the extreme ends of therapy spectrum. Patients: Clinical data and course of treatment of five long-term treated patients with cervical dystonia out of therapy response norms are presented: a patient who was supersensitive to standard dose and has required dose adjustment to lower dose of BoNT; one patient who worsened under a standard dose, but responded excellently to twice the standard dose; one insensitive patient who responded poorly for years to a dose well above the standard dose, but responded when dose was further increased; and two patients with a totally different response pattern to BoNT/A preparation 1, but the development of a neutralizing antibody induced secondary treatment failure in both cases and a totally different response after switch to BoNT/A preparation 2. Conclusions: These five patients indicate that the response of a patient to a BoNT preparation may be unexpected. Therefore, cautious onset of BoNT therapy is recommended as well as consequent dose adjustment later on and even switch to another BoNT/A preparation when a patient has already developed NABs against BoNT/A. MDPI 2020-12-31 /pmc/articles/PMC7824374/ /pubmed/33396548 http://dx.doi.org/10.3390/toxins13010022 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Samadzadeh, Sara
Brauns, Raphaela
Hefter, Harald
The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
title The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
title_full The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
title_fullStr The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
title_full_unstemmed The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
title_short The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
title_sort extreme ends of the treatment response spectrum to botulinum toxin in cervical dystonia
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824374/
https://www.ncbi.nlm.nih.gov/pubmed/33396548
http://dx.doi.org/10.3390/toxins13010022
work_keys_str_mv AT samadzadehsara theextremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia
AT braunsraphaela theextremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia
AT hefterharald theextremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia
AT samadzadehsara extremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia
AT braunsraphaela extremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia
AT hefterharald extremeendsofthetreatmentresponsespectrumtobotulinumtoxinincervicaldystonia